SynthesisOncotarget2016

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.

Maria Saveria Rotundo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.